Investigational drug · Phase 3
RSVpreF Vaccine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus, Respiratory Syncytial Virus (RSV).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
34
Any phase or sponsor naming "RSVpreF Vaccine"
First trial start
2024
Mar 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSVpreF Vaccine", any sponsor or status.
- Phase 317
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus
- Respiratory Syncytial Virus (RSV)
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "RSVpreF Vaccine" as an intervention, largest first.
- Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in AdultsPivotal-lookingActive, not recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT06684743 · 690,000 participants (planned) · Start Nov 18, 2024 · Primary completion May 2028
Drug: RSV prefusion F protein-based vaccine · For: RSV
Sites: Copenhagen, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05035212 · 38,861 participants · Start Aug 31, 2021 · Primary completion Jan 18, 2027
Drug: RSVpreF; Placebo · For: Lower Respiratory Tract Illness
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 263 sites in all
- A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04424316 · 14,727 participants · Start Jun 17, 2020 · Primary completion Oct 27, 2023
Drug: RSVpreF; Placebo · For: Respiratory Tract Infection
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 464 sites in all
- A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.Pivotal-lookingRecruiting
University of Witwatersrand, South AfricaAcademic, hospital or other
NCT06955728 · 13,000 participants (planned) · Start Sep 3, 2025 · Primary completion Feb 29, 2028
Drug: Vaccine · For: RSV Infections; RSV Immunisation; Preterm Labour
Sites: Kintampo, Ghana; Dodowa, Ghana; Kilifi, Kenya · 11 sites in all
- TARSILA Real-World Evidence StudyRecruiting
Inova MedicalAcademic, hospital or other
NCT07445763 · 5,000 participants (planned) · Start Apr 27, 2026 · Primary completion Sep 30, 2028
Drug: respiratory syncytial virus bivalent prefusion F vaccine · For: Respiratory Syncytial Virus (RSV); Maternal Immunization; Acute Respiratory Illness (ARI) and 2 more
Sites: Cascavel, Brazil; Curitiba, Brazil; Marechal Cândido Rondon, Brazil · 8 sites in all
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of AgePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05301322 · 1,471 participants · Start Apr 13, 2022 · Primary completion Oct 12, 2022
Drug: RSVpreF Vaccine; Seasonal Inactivated Influenza Vaccine · For: Respiratory Syncytial Virus
Sites: Bruce, Australia; Blacktown, Australia; Botany, Australia · 33 sites in all
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05886777 · 1,142 participants · Start Jun 5, 2023 · Primary completion Jan 1, 2024
Drug: Combination [RSVpreF+BNTb162b2]; Bivalent BNT162b2 (original/Omi BA.4/BA.5) and 3 more · For: Healthy Participants
Sites: Dublin, California; Huntington Beach, California; Lake Forest, California · 37 sites in all
- SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDERActive, not recruiting
PfizerPfizer (PFE)
NCT06546800 · 1,100 participants (planned) · Start May 27, 2025 · Primary completion Oct 28, 2027
Drug: RSVpreF vaccine · For: Respiratory Syncytial Virus Infection
Sites: Tokyo, Japan
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in BogotáActive, not recruiting
Bogotá District Health SecretariatGovernment (non-federal)
NCT07279298 · 1,097 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2026
Drug: RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposed · For: Respiratory Syncytial Virus Infections; Severe Acute Respiratory Infection; Bronchiolitis, Viral and 1 more
Sites: Bogotá, Colombia
- Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of AgePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05096208 · 1,028 participants · Start Oct 21, 2021 · Primary completion Apr 4, 2022
Drug: RSVpreF (Group 1); RSVpreF (Group 2) and 2 more · For: RSV
Sites: Miami Lakes, Florida; Sunrise, Florida; Winter Park, Florida · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis.
Batool R, Wang R, Obeid H, et al. · JAMA Pediatr 2026
- Quality Improvement Initiative to Increase Newborn RSV Immunization.
Daneshvari SW, Nemerofsky SL · Am J Med Qual 2026
- Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants.
Wadia U, Ong MM, Cox SN, et al. · JAMA Pediatr 2026
- Vaccination in Pregnancy with the Bivalent Respiratory Syncytial Virus Vaccine Elicits Significant Specific IgA, IgG, and Secretory Antibody Titers in Human Milk.
Atwell JE, Deese J, Suárez-Fariñas M, et al. · Breastfeed Med 2026
- Efficacy, Effectiveness, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Vaccine Administered During Pregnancy: Protocol for a Living Systematic Review and Meta-Analysis.
Mazzoni A, Bardach A, Berrueta M, et al. · JMIR Res Protoc 2026
- A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.
Fahfouhi Y, Fiévez S, Cohen R, et al. · Vaccine 2026
Also in development for Respiratory Syncytial Virus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.